We are delighted to announce that our abstract has been accepted for presentation at ISPOR US confer...
Read moreFrom July 2016 NICE will gain decision power by saying yes, no or maybe to cancer drugs entering the...
Read moreThe methodology to be used within the cost-effectiveness HTA evaluations is likely to be based on a ...
Read moreSome governments have looked to collective procurement with other countries, to in theory result in ...
Read moreThere are now European platforms for seeking early scientific advice with multiple payer organisatio...
Read moreThe aim of MAPPs is to enable quicker access for patients whilst providing adequate and evolving evi...
Read moreBased on the current clinical data, the PCSK9 inhibitors are a vital new treatment option for patien...
Read moreThe aim of this study was to assess the launch price of mCRPC treatments across the EU5 (France, Ger...
Read moreIncluded is the P&R challenges faced by the PCSK9 inhibitors as well as how payers are trying to ove...
Read moreIt is the responsibility of CCGs to manage their local drug budgets
Read more